New targeted therapies for adrenocortical carcinomas.

New targeted therapies for adrenocortical carcinomas. Minerva Endocrinol. 2018 May 28;: Authors: Manso J, Pezzani R Abstract Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis. It has been undergone to in-depth clinical and laboratory investigations, with the help of the most important research groups of all over the world. Nonetheless the cure for this kind of neoplasia is not right around the corner, given its complexity and multi-faceted feature, that lead researchers to think at "one person one ACC". Currently total resection is the most concrete option for ACC patients, whenever possible. Although years are still necessary for an effective treatment, indubitably the use of mitotane, among the available pharmacological treatments, in the early 60's revolutionized the approach to this rare disease. Mitotane remains the main drug for primary or adjuvant therapy, or for recurrent or relapsing disease, alone or combined to other chemotherapeutics. Yet, mitotane gives partial and unsatisfactory therapeutic results, especially in metastatic ACC. This prompted the researchers to find other ways to fight against this malignancy: targeted therapy seems the most promising answer, as it is based on biomolecular and genetic cancer signature. Many efforts are needed to continue the therapeutic exploration of ACC, but certainly we are on the right way. PMID: 29808641 [PubMed - as supplied by publisher]
Source: Minerva Endocrinologica - Category: Endocrinology Tags: Minerva Endocrinol Source Type: research